Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Adam S. Cheifetz, M.D.

Title
Institution
Department
Address
Phone
Fax

Bibliographic
selected publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Rakowsky S, Cheifetz AS, Papamichael K. Editorial: is there a role for monitoring intermediate anti-TNF drug concentrations in IBD? Aliment Pharmacol Ther. 2022 Apr; 55(8):1049-1050. PMID: 35362141.
    Citations:    Fields:    
  2. Sousa Freitas Queiroz N, Papamichael K, Cheifetz AS. Letter: is blindly stopping thiopurines without confirming adequate anti-TNF concentrations shortsighted? Aliment Pharmacol Ther. 2022 Apr; 55(7):887-888. PMID: 35315108.
    Citations:    Fields:    
  3. Papamichael K, Jairath V, Zou G, Cohen B, Ritter T, Sands B, Siegel C, Valentine J, Smith M, Vande Casteele N, Dubinsky M, Cheifetz A. Proactive infliximab optimisation using a pharmacokinetic dashboard versus standard of care in patients with Crohn's disease: study protocol for a randomised, controlled, multicentre, open-label study (the OPTIMIZE trial). BMJ Open. 2022 Apr 01; 12(4):e057656. PMID: 35365535.
    Citations:    Fields:    
  4. Grossberg LB, Papamichael K, Cheifetz AS. Review article: emerging drug therapies in inflammatory bowel disease. Aliment Pharmacol Ther. 2022 Apr; 55(7):789-804. PMID: 35166398.
    Citations:    Fields:    
  5. Rakowsky S, Papamichael K, Cheifetz AS. Choosing the right biologic for complications of inflammatory bowel disease. Expert Rev Gastroenterol Hepatol. 2022 Mar; 16(3):235-249. PMID: 35094628.
    Citations:    Fields:    
  6. Papamichael K, Afif W, Drobne D, Dubinsky MC, Ferrante M, Irving PM, Kamperidis N, Kobayashi T, Kotze PG, Lambert J, Noor NM, Roblin X, Roda G, Vande Casteele N, Yarur AJ, Arebi N, Danese S, Paul S, Sandborn WJ, Vermeire S, Cheifetz AS, Peyrin-Biroulet L. Therapeutic drug monitoring of biologics in inflammatory bowel disease: unmet needs and future perspectives. Lancet Gastroenterol Hepatol. 2022 02; 7(2):171-185. PMID: 35026171.
    Citations:    Fields:    Translation:Humans
  7. Papamichael K, Cheifetz AS. Optimizing therapeutic drug monitoring in inflammatory bowel disease: a focus on therapeutic monoclonal antibodies. Expert Opin Drug Metab Toxicol. 2021 Dec; 17(12):1423-1431. PMID: 34996330.
    Citations:    Fields:    
  8. Syal G, Sparrow MP, Velayos F, Cheifetz AS, Devlin S, Irving PM, Kaplan GG, Raffals LE, Ullman T, Gecse KB, Fleshner PR, Lightner AL, Siegel CA, Melmed GY. Appropriateness of Medical and Surgical Treatments for Chronic Pouchitis Using RAND/UCLA Appropriateness Methodology. Dig Dis Sci. 2022 Jan 10. PMID: 35006492.
    Citations:    Fields:    
  9. El-Dallal M, Saroufim A, Systrom H, Ballou S, Farhoud A, Pasam RT, Gadupudi SS, Osman K, Chaudrey K, Cheifetz A, Feuerstein JD. Assessing the repercussions of COVID-19 pandemic on symptoms, disease management, and emotional well-being in patients with inflammatory bowel disease: a multi-site survey study. Scand J Gastroenterol. 2021 Dec 11; 1-9. PMID: 34894999.
    Citations:    Fields:    
  10. Nones RB, Fleshner PR, Queiroz NSF, Cheifetz AS, Spinelli A, Danese S, Peyrin-Biroulet L, Papamichael K, Kotze PG. Therapeutic Drug Monitoring of Biologics in IBD: Essentials for the Surgical Patient. J Clin Med. 2021 Nov 29; 10(23). PMID: 34884344.
    Citations:    
  11. Gianotti RJ, Cheifetz AS. Cannabis and Inflammatory Bowel Disease: All Smoke and Mirrors? J Crohns Colitis. 2021 Nov 08; 15(11):1785-1786. PMID: 34137450.
    Citations:    Fields:    Translation:HumansAnimals
  12. Syal G, Serrano M, Jain A, Cohen BL, Rieder F, Stone C, Abraham B, Hudesman D, Malter L, McCabe R, Holubar S, Afzali A, Cheifetz AS, Gaidos JKJ, Moss AC. Health Maintenance Consensus for Adults With Inflammatory Bowel Disease. Inflamm Bowel Dis. 2021 10 18; 27(10):1552-1563. PMID: 34279600.
    Citations:    Fields:    Translation:Humans
  13. Cheifetz AS, Abreu MT, Afif W, Cross RK, Dubinsky MC, Loftus EV, Osterman MT, Saroufim A, Siegel CA, Yarur AJ, Melmed GY, Papamichael K. A Comprehensive Literature Review and Expert Consensus Statement on Therapeutic Drug Monitoring of Biologics in Inflammatory Bowel Disease. Am J Gastroenterol. 2021 10 01; 116(10):2014-2025. PMID: 34388143.
    Citations: 3     Fields:    Translation:Humans
  14. Rakowsky S, Cheifetz AS, Papamichael K. Editorial: higher concentrations of cytokine blockers are needed to obtain small bowel mucosal healing during maintenance therapy in Crohn's disease. Aliment Pharmacol Ther. 2021 10; 54(8):1085-1086. PMID: 34564884.
    Citations:    Fields:    Translation:Humans
  15. Papamichael K, Dubinsky MC, Cheifetz AS. Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction in Patients With Chronic Immune-Mediated Inflammatory Diseases. JAMA. 2021 09 21; 326(11):1067. PMID: 34546306.
    Citations: 1     Fields:    Translation:Humans
  16. Edgar BS, Cheifetz AS, Helfgott SM, Smith GP, Bandekar T, Hoye-Simek A, Liu Y, Singh RM, Fajardo KI, Carter J, Simone L. Overcoming barriers to biosimilar adoption: real-world perspectives from a national payer and provider initiative. J Manag Care Spec Pharm. 2021 Aug; 27(8):1129-1135. PMID: 34337986.
    Citations: 1     Fields:    Translation:Humans
  17. Grossberg LB, Pellish RS, Cheifetz AS, Feuerstein JD. Review of Societal Recommendations Regarding Management of Patients With Inflammatory Bowel Disease During the SARS-CoV-2 Pandemic. Inflamm Bowel Dis. 2021 05 17; 27(6):940-946. PMID: 32619010.
    Citations: 3     Fields:    Translation:HumansCellsPHPublic Health
  18. Papamichael K, Vande Casteele N, Jeyarajah J, Jairath V, Osterman MT, Cheifetz AS. Higher Postinduction Infliximab Concentrations Are Associated With Improved Clinical Outcomes in Fistulizing Crohn's Disease: An ACCENT-II Post Hoc Analysis. Am J Gastroenterol. 2021 05 01; 116(5):1007-1014. PMID: 33929379.
    Citations: 3     Fields:    Translation:Humans
  19. Llanos-Chea A, Shapiro JM, Winter RW, Jerger L, Menz T, Gibson M, Friedmann AM, Treaba D, Papamichael K, Cheifetz AS, Friedman S, Hamilton MJ, Winter HS. Lymphoma in Pediatric-Onset Inflammatory Bowel Disease Treated with Infliximab Monotherapy: A Case Series. Dig Dis Sci. 2022 01; 67(1):252-258. PMID: 33595782.
    Citations:    Fields:    Translation:HumansCells
  20. Vande Casteele N, Abreu MT, Flier S, Papamichael K, Rieder F, Silverberg MS, Khanna R, Okada L, Yang L, Jain A, Cheifetz AS. Patients With Low Drug Levels or Antibodies to a Prior Anti-Tumor Necrosis Factor Are More Likely to Develop Antibodies to a Subsequent Anti-Tumor Necrosis Factor. Clin Gastroenterol Hepatol. 2022 02; 20(2):465-467.e2. PMID: 33421628.
    Citations: 2     Fields:    
  21. Papamichael K, Cheifetz AS. Therapeutic Drug Monitoring and Safety of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease. Clin Gastroenterol Hepatol. 2021 04; 19(4):854-855. PMID: 33248082.
    Citations:    Fields:    Translation:Humans
  22. Harshe RP, Xie A, Vuerich M, Frank LA, Gromova B, Zhang H, Robles RJ, Mukherjee S, Csizmadia E, Kokkotou E, Cheifetz AS, Moss AC, Kota SK, Robson SC, Longhi MS. Endogenous antisense RNA curbs CD39 expression in Crohn's disease. Nat Commun. 2020 11 18; 11(1):5894. PMID: 33208731.
    Citations: 5     Fields:    Translation:HumansAnimalsCells
  23. Vaughn BP, Yarur AJ, Graziano E, Campbell JP, Bhattacharya A, Lee JY, Gheysens K, Papamichael K, Osterman MT, Cheifetz AS, Cross RK. Vedolizumab Serum Trough Concentrations and Response to Dose Escalation in Inflammatory Bowel Disease. J Clin Med. 2020 Sep 28; 9(10). PMID: 32998473.
    Citations: 3     
  24. Papamichael K, Thomas VJ, Banty A, Clarke WT, Germansky KA, Flier SN, Feuerstein JD, Melmed GY, Cheifetz AS. Clinical Impact of Corrections to Infliximab and Adalimumab Monitoring Results with the Homogeneous Mobility Shift Assay. J Clin Med. 2020 Sep 02; 9(9). PMID: 32887317.
    Citations:    
  25. Malter L, Jain A, Cohen BL, Gaidos JKJ, Axisa L, Butterfield L, Rescola BJ, Sarode S, Ehrlich O, Cheifetz AS. Identifying IBD Providers' Knowledge Gaps Using a Prospective Web-based Survey. Inflamm Bowel Dis. 2020 08 20; 26(9):1445-1450. PMID: 32100018.
    Citations: 1     Fields:    Translation:Humans
  26. El-Dallal M, Chen Y, Lin Q, Rakowsky S, Sattler L, Foromera J, Grossberg L, Cheifetz AS, Feuerstein JD. Meta-analysis of Virtual-based Chromoendoscopy Compared With Dye-spraying Chromoendoscopy Standard and High-definition White Light Endoscopy in Patients With Inflammatory Bowel Disease at Increased Risk of Colon Cancer. Inflamm Bowel Dis. 2020 08 20; 26(9):1319-1329. PMID: 32034916.
    Citations: 7     Fields:    Translation:Humans
  27. Papamichael K, Cheifetz AS. Proactive Adalimumab Monitoring in Inflammatory Bowel Disease: Current Data and Future Perspectives. J Crohns Colitis. 2020 07 09; 14(6):878-879. PMID: 31761938.
    Citations:    Fields:    Translation:Humans
  28. Papamichael K, Cheifetz AS. Therapeutic drug monitoring in patients on biologics: lessons from gastroenterology. Curr Opin Rheumatol. 2020 07; 32(4):371-379. PMID: 32412995.
    Citations: 3     Fields:    Translation:Humans
  29. Grossberg LB, Farraye FA, Papamichael K, Cheifetz AS, Feuerstein JD. A Survey Study of Gastroenterologists' Views on Dysplasia Surveillance and Chromoendoscopy in IBD. Inflamm Bowel Dis. 2020 06 18; 26(7):e59-e61. PMID: 32304571.
    Citations:    Fields:    Translation:HumansPHPublic Health
  30. Papamichael K, Clarke WT, Vande Casteele N, Germansky KA, Feuerstein JD, Melmed GY, Siegel CA, Irving PM, Cheifetz AS. Comparison of Assays for Therapeutic Monitoring of Infliximab and Adalimumab in Patients With Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol. 2021 04; 19(4):839-841.e2. PMID: 32147594.
    Citations: 2     Fields:    Translation:Humans
  31. Feuerstein JD, Cheifetz AS. Response. Gastrointest Endosc. 2020 03; 91(3):719-720. PMID: 32087903.
    Citations:    Fields:    Translation:Humans
  32. Papamichael K, Cheifetz AS, Irving PM. New role for azathioprine in case of switching anti-TNFs in IBD. Gut. 2020 07; 69(7):1165-1167. PMID: 32075889.
    Citations: 2     Fields:    Translation:Humans
  33. Negoescu DM, Enns EA, Swanhorst B, Baumgartner B, Campbell JP, Osterman MT, Papamichael K, Cheifetz AS, Vaughn BP. Proactive Vs Reactive Therapeutic Drug Monitoring of Infliximab in Crohn's Disease: A Cost-Effectiveness Analysis in a Simulated Cohort. Inflamm Bowel Dis. 2020 01 01; 26(1):103-111. PMID: 31184366.
    Citations: 6     Fields:    Translation:Humans
  34. Fine S, Papamichael K, Cheifetz AS. Etiology and Management of Lack or Loss of Response to Anti-Tumor Necrosis Factor Therapy in Patients With Inflammatory Bowel Disease. Gastroenterol Hepatol (N Y). 2019 Dec; 15(12):656-665. PMID: 31892912.
    Citations: 12     
  35. Frasca JD, Cheifetz AS. The cost and benefit of anti-TNF therapy from a population perspective-for what it's worth. Ann Transl Med. 2019 Dec; 7(Suppl 8):S388. PMID: 32016106.
    Citations:    
  36. Clarke WT, Papamichael K, Vande Casteele N, Germansky KA, Feuerstein JD, Melmed GY, Siegel CA, Irving PM, Cheifetz AS. Infliximab and Adalimumab Concentrations May Vary Between the Enzyme-Linked Immunosorbent Assay and the Homogeneous Mobility Shift Assay in Patients With Inflammatory Bowel Disease: A Prospective Cross-Sectional Observational Study. Inflamm Bowel Dis. 2019 10 18; 25(11):e143-e145. PMID: 31559417.
    Citations: 5     Fields:    Translation:Humans
  37. Sands BE, Cheifetz AS, Nduaka CI, Quirk D, Wang W, Maller E, Friedman GS, Su C, Higgins PDR. The Impact of Raising the Bar for Clinical Trials in Ulcerative Colitis. J Crohns Colitis. 2019 Sep 19; 13(9):1217-1226. PMID: 30879034.
    Citations: 2     Fields:    Translation:Humans
  38. Frasca JD, Cheifetz AS. Editorial: real-world short-term effectiveness of ustekinumab in 305 patients with Crohn's disease-results from the ENEIDA registry. Aliment Pharmacol Ther. 2019 09; 50(5):599-600. PMID: 31414548.
    Citations:    Fields:    Translation:Humans
  39. Papamichael K, Juncadella A, Wong D, Rakowsky S, Sattler LA, Campbell JP, Vaughn BP, Cheifetz AS. Proactive Therapeutic Drug Monitoring of Adalimumab Is Associated With Better Long-term Outcomes Compared With Standard of Care in Patients With Inflammatory Bowel Disease. J Crohns Colitis. 2019 Aug 14; 13(8):976-981. PMID: 30689771.
    Citations: 23     Fields:    Translation:Humans
  40. Papamichael K, Papaioannou G, Cheifetz MA, Cheifetz AS. Bone of Contention: Helicobacter pylori and Osteoporosis-Is There an Association? Dig Dis Sci. 2019 10; 64(10):2736-2739. PMID: 31407131.
    Citations: 2     Fields:    Translation:HumansCells
  41. Papamichael K, Cheifetz AS. Is It Prime Time for Proactive Therapeutic Drug Monitoring of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease? Gastroenterology. 2019 10; 157(4):922-924. PMID: 31400368.
    Citations: 1     Fields:    Translation:Humans
  42. Papamichael K, Cheifetz AS. Therapeutic drug monitoring in inflammatory bowel disease: for every patient and every drug? Curr Opin Gastroenterol. 2019 07; 35(4):302-310. PMID: 30973355.
    Citations: 8     Fields:    Translation:Humans
  43. Papamichael K, Vogelzang EH, Lambert J, Wolbink G, Cheifetz AS. Therapeutic drug monitoring with biologic agents in immune mediated inflammatory diseases. Expert Rev Clin Immunol. 2019 08; 15(8):837-848. PMID: 31180729.
    Citations: 17     Fields:    Translation:Humans
  44. Papamichael K, Cheifetz AS. Integrin Calculus: The Predictive Power of Vedolizumab Concentrations in IBD Therapy. Dig Dis Sci. 2019 06; 64(6):1397-1398. PMID: 30927210.
    Citations:    Fields:    Translation:Humans
  45. Lin SC, Goldowsky A, Papamichael K, Cheifetz AS. The Treatment of Inflammatory Bowel Disease in Patients With a History of Malignancy. Inflamm Bowel Dis. 2019 05 04; 25(6):998-1005. PMID: 30590558.
    Citations: 1     Fields:    Translation:Humans
  46. Feuerstein JD, Rakowsky S, Sattler L, Yadav A, Foromera J, Grossberg L, Cheifetz AS. Meta-analysis of dye-based chromoendoscopy compared with standard- and high-definition white-light endoscopy in patients with inflammatory bowel disease at increased risk of colon cancer. Gastrointest Endosc. 2019 08; 90(2):186-195.e1. PMID: 31009609.
    Citations: 14     Fields:    Translation:Humans
  47. Papamichael K, Cheifetz AS, Melmed GY, Irving PM, Vande Casteele N, Kozuch PL, Raffals LE, Baidoo L, Bressler B, Devlin SM, Jones J, Kaplan GG, Sparrow MP, Velayos FS, Ullman T, Siegel CA. Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol. 2019 08; 17(9):1655-1668.e3. PMID: 30928454.
    Citations: 54     Fields:    Translation:Humans
  48. Papamichael K, Lin S, Moore M, Papaioannou G, Sattler L, Cheifetz AS. Infliximab in inflammatory bowel disease. Ther Adv Chronic Dis. 2019; 10:2040622319838443. PMID: 30937157.
    Citations: 17     
  49. Swaminath A, Berlin EP, Cheifetz A, Hoffenberg E, Kinnucan J, Wingate L, Buchanan S, Zmeter N, Rubin DT. The Role of Cannabis in the Management of Inflammatory Bowel Disease: A Review of Clinical, Scientific, and Regulatory Information. Inflamm Bowel Dis. 2019 02 21; 25(3):427-435. PMID: 30358848.
    Citations: 11     Fields:    Translation:Humans
  50. Papamichael K, Rakowsky S, Rivera C, Cheifetz AS, Osterman MT. Association Between Serum Infliximab Trough Concentrations During Maintenance Therapy and Biochemical, Endoscopic, and Histologic Remission in Crohn's Disease. Inflamm Bowel Dis. 2018 09 15; 24(10):2266-2271. PMID: 29718327.
    Citations: 19     Fields:    Translation:Humans
  51. Hanauer S, Panaccione R, Danese S, Cheifetz A, Reinisch W, Higgins PDR, Woodworth DA, Zhang H, Friedman GS, Lawendy N, Quirk D, Nduaka CI, Su C. Tofacitinib Induction Therapy Reduces Symptoms Within 3 Days for Patients With Ulcerative Colitis. Clin Gastroenterol Hepatol. 2019 01; 17(1):139-147. PMID: 30012431.
    Citations: 37     Fields:    Translation:Humans
  52. Juncadella A, Papamichael K, Vaughn BP, Cheifetz AS. Maintenance Adalimumab Concentrations Are Associated with Biochemical, Endoscopic, and Histologic Remission in Inflammatory Bowel Disease. Dig Dis Sci. 2018 11; 63(11):3067-3073. PMID: 30006816.
    Citations: 18     Fields:    Translation:Humans
  53. Lin SC, Cheifetz AS. The Use of Complementary and Alternative Medicine in Patients With Inflammatory Bowel Disease. Gastroenterol Hepatol (N Y). 2018 Jul; 14(7):415-425. PMID: 30166957.
    Citations: 10     
  54. Papamichael K, Vajravelu RK, Vaughn BP, Osterman MT, Cheifetz AS. Proactive Infliximab Monitoring Following Reactive Testing is Associated With Better Clinical Outcomes Than Reactive Testing Alone in Patients With Inflammatory Bowel Disease. J Crohns Colitis. 2018 Jun 28; 12(7):804-810. PMID: 29590345.
    Citations: 28     Fields:    Translation:Humans
  55. Papamichael K, Cheifetz AS. Letter: infliximab concentrations during induction therapy-one size does not fit all. Aliment Pharmacol Ther. 2018 05; 47(9):1334-1335. PMID: 29644743.
    Citations: 1     Fields:    Translation:Humans
  56. Papamichael K, Cheifetz AS, Osterman MT. Reply. Clin Gastroenterol Hepatol. 2018 04; 16(4):598-599. PMID: 29555231.
    Citations:    Fields:    Translation:Humans
  57. Clarke WT, Amin SS, Papamichael K, Feuerstein JD, Cheifetz AS. Patients with core antibody positive and surface antigen negative Hepatitis B (anti-HBc+, HBsAg-) on anti-TNF therapy have a low rate of reactivation. Clin Immunol. 2018 06; 191:59-62. PMID: 29601854.
    Citations: 2     Fields:    Translation:HumansCells
  58. Katsanos KH, Papamichael K, Feuerstein JD, Christodoulou DK, Cheifetz AS. Biological therapies in inflammatory bowel disease: Beyond anti-TNF therapies. Clin Immunol. 2019 09; 206:9-14. PMID: 29545207.
    Citations: 24     Fields:    Translation:Humans
  59. Melmed GY, Kaplan GG, Sparrow MP, Velayos FS, Baidoo L, Bressler B, Cheifetz AS, Devlin SM, Irving PM, Jones J, Kozuch PL, Raffals LE, Siegel CA. Appropriateness of Combination Therapy for Patients With Inflammatory Bowel Diseases: One Size Still Does Not Fit All. Clin Gastroenterol Hepatol. 2018 11; 16(11):1829-1831. PMID: 29505910.
    Citations:    Fields:    Translation:Humans
  60. Katsanos KH, Papamichael K, Cheifetz AS, Christodoulou DK. Full Interchangeability in Regards to Immunogenicity Between the Infliximab Reference Biologic and Biosimilars CT-P13 and SB2 in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2018 02 15; 24(3):465-466. PMID: 29462402.
    Citations:    Fields:    Translation:Humans
  61. Papamichael K, Osterman MT, Siegel CA, Melmed GY, Dubinsky MC, Colombel JF, Hanauer SB, Cheifetz AS. Using Proactive Therapeutic Drug Monitoring of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease: From an Old Concept to a Future Standard of Care? Gastroenterology. 2018 03; 154(4):1201-1202. PMID: 29432749.
    Citations: 7     Fields:    Translation:Humans
  62. Ballou S, Hirsch W, Singh P, Rangan V, Nee J, Iturrino J, Sommers T, Zubiago J, Sengupta N, Bollom A, Jones M, Moss AC, Flier SN, Cheifetz AS, Lembo A. Emergency department utilisation for inflammatory bowel disease in the United States from 2006 to 2014. Aliment Pharmacol Ther. 2018 Apr; 47(7):913-921. PMID: 29411411.
    Citations: 10     Fields:    Translation:Humans
  63. Papamichael K, Cheifetz AS. Editorial: early post-induction anti-TNF drug monitoring can predict long-term therapeutic outcomes in inflammatory bowel disease. Aliment Pharmacol Ther. 2018 02; 47(3):436-437. PMID: 29314123.
    Citations:    Fields:    Translation:Humans
  64. Papamichael K, Vajravelu RK, Osterman MT, Cheifetz AS. Long-Term Outcome of Infliximab Optimization for Overcoming Immunogenicity in Patients with Inflammatory Bowel Disease. Dig Dis Sci. 2018 03; 63(3):761-767. PMID: 29340807.
    Citations: 9     Fields:    Translation:Humans
  65. Hui KY, Fernandez-Hernandez H, Hu J, Schaffner A, Pankratz N, Hsu NY, Chuang LS, Carmi S, Villaverde N, Li X, Rivas M, Levine AP, Bao X, Labrias PR, Haritunians T, Ruane D, Gettler K, Chen E, Li D, Schiff ER, Pontikos N, Barzilai N, Brant SR, Bressman S, Cheifetz AS, Clark LN, Daly MJ, Desnick RJ, Duerr RH, Katz S, Lencz T, Myers RH, Ostrer H, Ozelius L, Payami H, Peter Y, Rioux JD, Segal AW, Scott WK, Silverberg MS, Vance JM, Ubarretxena-Belandia I, Foroud T, Atzmon G, Pe'er I, Ioannou Y, McGovern DPB, Yue Z, Schadt EE, Cho JH, Peter I. Functional variants in the LRRK2 gene confer shared effects on risk for Crohn's disease and Parkinson's disease. Sci Transl Med. 2018 01 10; 10(423). PMID: 29321258.
    Citations: 103     Fields:    Translation:HumansCells
  66. Grossberg LB, Papamichael K, Feuerstein JD, Siegel CA, Ullman TA, Cheifetz AS. A Survey Study of Gastroenterologists' Attitudes and Barriers Toward Therapeutic Drug Monitoring of Anti-TNF Therapy in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2017 12 19; 24(1):191-197. PMID: 29272486.
    Citations: 16     Fields:    Translation:Humans
  67. Papamichael K, Rakowsky S, Rivera C, Cheifetz AS, Osterman MT. Infliximab trough concentrations during maintenance therapy are associated with endoscopic and histologic healing in ulcerative colitis. Aliment Pharmacol Ther. 2018 02; 47(4):478-484. PMID: 29210094.
    Citations: 23     Fields:    Translation:Humans
  68. Papamichael K, Cheifetz AS. Response to Reinink. Am J Gastroenterol. 2017 12; 112(12):1893-1894. PMID: 29215625.
    Citations:    Fields:    
  69. Boyle MP, Moss AC, O'Toole AM, Vaughn B, Cheifetz AS. C-reactive protein as a predictor of low trough infliximab concentrations in patients who lose response to infliximab. J Dig Dis. 2017 Dec; 18(12):678-683. PMID: 29119722.
    Citations: 1     Fields:    Translation:Humans
  70. Feuerstein JD, Papamichael K, Popejoy S, Nadelson A, Lewandowski JJ, Geissler K, Martinez-Vazquez M, Leffler DA, Ariyabuddhiphongs K, Thukral C, Cheifetz AS. Targeted Physician Education and Standardizing Documentation Improves Documented Reporting with Inflammatory Bowel Disease Quality Measures in a Large Academic and Private Practice. Dig Dis Sci. 2018 01; 63(1):36-45. PMID: 29147880.
    Citations: 2     Fields:    Translation:Humans
  71. Katsanos KH, Papamichael K, Christodoulou DK, Cheifetz AS. Histological healing beyond endoscopic healing in ulcerative colitis: Shall we target the "ultra-deep" remission? Dig Liver Dis. 2017 12; 49(12):1332-1333. PMID: 28964677.
    Citations:    Fields:    Translation:Humans
  72. Papamichael K, Cheifetz AS. Defining and predicting deep remission in patients with perianal fistulizing Crohn's disease on anti-tumor necrosis factor therapy. World J Gastroenterol. 2017 Sep 14; 23(34):6197-6200. PMID: 28974885.
    Citations: 4     Fields:    Translation:Humans
  73. Cheifetz A. Overview of Therapeutic Drug Monitoring of Biologic Agents in Patients With Inflammatory Bowel Disease. Gastroenterol Hepatol (N Y). 2017 Sep; 13(9):556-559. PMID: 29038648.
    Citations: 3     
  74. Papamichael K, Vande Casteele N, Ferrante M, Gils A, Cheifetz AS. Therapeutic Drug Monitoring During Induction of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease: Defining a Therapeutic Drug Window. Inflamm Bowel Dis. 2017 09; 23(9):1510-1515. PMID: 28816757.
    Citations: 22     Fields:    Translation:Humans
  75. Feldbrügge L, Moss AC, Yee EU, Csizmadia E, Mitsuhashi S, Longhi MS, Sandhu B, Stephan H, Wu Y, Cheifetz AS, Müller CE, Sévigny J, Robson SC, Jiang ZG. Expression of Ecto-nucleoside Triphosphate Diphosphohydrolases-2 and -3 in the Enteric Nervous System Affects Inflammation in Experimental Colitis and Crohn's Disease. J Crohns Colitis. 2017 Sep 01; 11(9):1113-1123. PMID: 28472257.
    Citations: 9     Fields:    Translation:HumansAnimals
  76. Papamichael K, Casteele NV, Ferrante M, Gils A, Cheifetz AS. Therapeutic Drug Monitoring During Induction of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease: Defining a Therapeutic Drug Window. Inflamm Bowel Dis. 2017 Aug 14. PMID: 28816748.
    Citations:    
  77. Papamichael K, Osterman MT, Cheifetz AS. Reply. Clin Gastroenterol Hepatol. 2017 10; 15(10):1638-1639. PMID: 28603051.
    Citations:    Fields:    Translation:Humans
  78. Feuerstein JD, Cheifetz AS. Crohn Disease: Epidemiology, Diagnosis, and Management. Mayo Clin Proc. 2017 07; 92(7):1088-1103. PMID: 28601423.
    Citations: 78     Fields:    Translation:Humans
  79. Burke KE, Haviland MJ, Hacker MR, Shainker SA, Cheifetz AS. Indications for Mode of Delivery in Pregnant Women with Inflammatory Bowel Disease. Inflamm Bowel Dis. 2017 05; 23(5):721-726. PMID: 28426453.
    Citations: 3     Fields:    Translation:Humans
  80. Papamichael K, Cheifetz AS. Editorial: therapeutic de-escalation of anti-tumour necrosis factor therapy - is less enough? Aliment Pharmacol Ther. 2017 05; 45(9):1265-1266. PMID: 28370052.
    Citations:    Fields:    Translation:Humans
  81. Papamichael K, Chachu KA, Vajravelu RK, Vaughn BP, Ni J, Osterman MT, Cheifetz AS. Improved Long-term Outcomes of Patients With Inflammatory Bowel Disease Receiving Proactive Compared With Reactive Monitoring of Serum Concentrations of Infliximab. Clin Gastroenterol Hepatol. 2017 Oct; 15(10):1580-1588.e3. PMID: 28365486.
    Citations: 61     Fields:    Translation:Humans
  82. Papamichael K, Cheifetz AS. Therapeutic Drug Monitoring in IBD: The New Standard-of-Care for Anti-TNF Therapy. Am J Gastroenterol. 2017 May; 112(5):673-676. PMID: 28220781.
    Citations: 24     Fields:    Translation:Humans
  83. Feuerstein JD, Sehgal P, Rao V, Malladi VR, Baroni E, Cheifetz AS. Inflammatory Bowel Disease-Related Abstracts Presented at National Conferences in the USA Are Frequently Unpublished as Full Manuscripts. Dig Dis Sci. 2017 Feb; 62(2):352-357. PMID: 27975235.
    Citations:    Fields:    
  84. Koliani-Pace J, Vaughn B, Herzig SJ, Davis RB, Gashin L, Obuch J, Cheifetz AS. Utility of Emergency Department Use of Abdominal Pelvic Computed Tomography in the Management of Crohn's Disease. J Clin Gastroenterol. 2016 Nov/Dec; 50(10):859-864. PMID: 26974753.
    Citations: 1     Fields:    Translation:Humans
  85. Cheifetz AS, Gianotti R, Luber R, Gibson PR. Complementary and Alternative Medicines Used by Patients With Inflammatory Bowel Diseases. Gastroenterology. 2017 02; 152(2):415-429.e15. PMID: 27743873.
    Citations: 39     Fields:    Translation:HumansAnimals
  86. Feuerstein JD, Sheppard V, Cheifetz AS, Ariyabuddhiphongs K. How to Develop the Medical Neighborhood. J Med Syst. 2016 Sep; 40(9):196. PMID: 27447470.
    Citations: 2     Fields:    
  87. Chuang LS, Villaverde N, Hui KY, Mortha A, Rahman A, Levine AP, Haritunians T, Evelyn Ng SM, Zhang W, Hsu NY, Facey JA, Luong T, Fernandez-Hernandez H, Li D, Rivas M, Schiff ER, Gusev A, Schumm LP, Bowen BM, Sharma Y, Ning K, Remark R, Gnjatic S, Legnani P, George J, Sands BE, Stempak JM, Datta LW, Lipka S, Katz S, Cheifetz AS, Barzilai N, Pontikos N, Abraham C, Dubinsky MJ, Targan S, Taylor K, Rotter JI, Scherl EJ, Desnick RJ, Abreu MT, Zhao H, Atzmon G, Pe'er I, Kugathasan S, Hakonarson H, McCauley JL, Lencz T, Darvasi A, Plagnol V, Silverberg MS, Muise AM, Brant SR, Daly MJ, Segal AW, Duerr RH, Merad M, McGovern DP, Peter I, Cho JH. A Frameshift in CSF2RB Predominant Among Ashkenazi Jews Increases Risk for Crohn's Disease and Reduces Monocyte Signaling via GM-CSF. Gastroenterology. 2016 10; 151(4):710-723.e2. PMID: 27377463.
    Citations: 26     Fields:    Translation:HumansCells
  88. Feuerstein JD, Castillo NE, Akbari M, Belkin E, Lewandowski JJ, Hurley CM, Lloyd S, Leffler DA, Cheifetz AS. Systematic Analysis and Critical Appraisal of the Quality of the Scientific Evidence and Conflicts of Interest in Practice Guidelines (2005-2013) for Barrett's Esophagus. Dig Dis Sci. 2016 10; 61(10):2812-2822. PMID: 27307064.
    Citations: 7     Fields:    Translation:Humans
  89. Devlin SM, Melmed GY, Irving PM, Rubin DT, Kornbluth A, Kozuch PL, Raffals LE, Velayos FS, Sparrow MP, Baidoo L, Bressler B, Cheifetz AS, Jones J, Kaplan GG, Siegel CA. Recommendations for Quality Colonoscopy Reporting for Patients with Inflammatory Bowel Disease: Results from a RAND Appropriateness Panel. Inflamm Bowel Dis. 2016 06; 22(6):1418-24. PMID: 27057680.
    Citations: 3     Fields:    Translation:Humans
  90. Wasan SK, Zullow S, Berg A, Cheifetz AS, Ganley-Leal L, Farraye FA. Herpes Zoster Vaccine Response in Inflammatory Bowel Disease Patients on Low-dose Immunosuppression. Inflamm Bowel Dis. 2016 06; 22(6):1391-6. PMID: 27057679.
    Citations: 14     Fields:    Translation:HumansCellsCTClinical Trials
  91. Melmed GY, Irving PM, Jones J, Kaplan GG, Kozuch PL, Velayos FS, Baidoo L, Sparrow MP, Bressler B, Cheifetz AS, Devlin SM, Raffals LE, Vande Casteele N, Mould DR, Colombel JF, Dubinsky M, Sandborn WJ, Siegel CA. Appropriateness of Testing for Anti-Tumor Necrosis Factor Agent and Antibody Concentrations, and Interpretation of Results. Clin Gastroenterol Hepatol. 2016 09; 14(9):1302-9. PMID: 27189916.
    Citations: 10     Fields:    Translation:Humans
  92. Feuerstein JD, Akbari M, Tapper EB, Cheifetz AS. Systematic review and meta-analysis of third-line salvage therapy with infliximab or cyclosporine in severe ulcerative colitis. Ann Gastroenterol. 2016 Jul-Sep; 29(3):341-7. PMID: 27366036.
    Citations: 9     
  93. Zenlea T, Yee EU, Rosenberg L, Boyle M, Nanda KS, Wolf JL, Falchuk KR, Cheifetz AS, Goldsmith JD, Moss AC. Histology Grade Is Independently Associated With Relapse Risk in Patients With Ulcerative Colitis in Clinical Remission: A Prospective Study. Am J Gastroenterol. 2016 05; 111(5):685-90. PMID: 26977756.
    Citations: 41     Fields:    Translation:Humans
  94. Papamichael K, Cheifetz AS. Use of anti-TNF drug levels to optimise patient management. Frontline Gastroenterol. 2016 Oct; 7(4):289-300. PMID: 28839870.
    Citations: 25     
  95. Oza SS, Pabby V, Dodge LE, Hacker MR, Fox JH, Moragianni VA, Correia K, Missmer SA, Ibrahim Y, Penzias AS, Burakoff R, Friedman S, Cheifetz AS. Factors Associated with the Success of In Vitro Fertilization in Women with Inflammatory Bowel Disease. Dig Dis Sci. 2016 08; 61(8):2381-2388. PMID: 26888767.
    Citations: 4     Fields:    Translation:Humans
  96. Papamichael K, Cheifetz AS. Higher Adalimumab Drug Levels Are Associated with Mucosal Healing in Patients with Crohn's Disease. J Crohns Colitis. 2016 May; 10(5):507-9. PMID: 26874348.
    Citations: 5     Fields:    Translation:Humans
  97. Boyle M, Ting A, Cury DB, Nanda K, Cheifetz AS, Moss A. Adherence to Rectal Mesalamine in Patients with Ulcerative Colitis. Inflamm Bowel Dis. 2015 Dec; 21(12):2873-8. PMID: 26313693.
    Citations: 5     Fields:    Translation:Humans
  98. Gibson DJ, Elliott L, McDermott E, Tosetto M, Keegan D, Byrne K, Martin ST, Rispens T, Cullen G, Mulcahy HE, Cheifetz AS, Moss AC, Robson SC, Doherty GA, Ryan EJ. Heightened Expression of CD39 by Regulatory T Lymphocytes Is Associated with Therapeutic Remission in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2015 Dec; 21(12):2806-14. PMID: 26332314.
    Citations: 26     Fields:    Translation:HumansAnimalsCells
  99. Feuerstein JD, Castillo NE, Siddique SS, Lewandowski JJ, Geissler K, Martinez-Vazquez M, Thukral C, Leffler DA, Cheifetz AS. Poor Documentation of Inflammatory Bowel Disease Quality Measures in Academic, Community, and Private Practice. Clin Gastroenterol Hepatol. 2016 Mar; 14(3):421-428.e2. PMID: 26499928.
    Citations: 10     Fields:    Translation:HumansPHPublic Health
  100. Feuerstein JD, Pelsis JR, Lloyd S, Cheifetz AS, Stone KR. Systematic analysis of the quality of the scientific evidence and conflicts of interest in osteoarthritis of the hip and knee practice guidelines. Semin Arthritis Rheum. 2016 Feb; 45(4):379-85. PMID: 26522136.
    Citations: 8     Fields:    Translation:Humans
  101. Feuerstein JD, Jiang ZG, Belkin E, Lewandowski JJ, Martinez-Vazquez M, Singla A, Cataldo T, Poylin V, Cheifetz AS. Surgery for Ulcerative Colitis Is Associated with a High Rate of Readmissions at 30 Days. Inflamm Bowel Dis. 2015 Sep; 21(9):2130-6. PMID: 26020605.
    Citations: 6     Fields:    Translation:Humans
  102. Gashin L, Cheifetz AS. Reply to Use of CT Scan in Ulcerative Colitis Patients Presenting to the Emergency Department. Inflamm Bowel Dis. 2015 Aug; 21(8):E21. PMID: 26197384.
    Citations:    Fields:    Translation:Humans
  103. Jones JL, Kaplan GG, Peyrin-Biroulet L, Baidoo L, Devlin S, Melmed GY, Tanyingoh D, Raffals L, Irving P, Kozuch P, Sparrow M, Velayos F, Bressler B, Cheifetz A, Colombel JF, Siegel CA. Effects of Concomitant Immunomodulator Therapy on Efficacy and Safety of Anti-Tumor Necrosis Factor Therapy for Crohn's Disease: A Meta-analysis of Placebo-controlled Trials. Clin Gastroenterol Hepatol. 2015 Dec; 13(13):2233-40.e1-2; quiz e177-8. PMID: 26142167.
    Citations: 33     Fields:    Translation:Humans
  104. Vaughn BP, Sandborn WJ, Cheifetz AS. Biologic concentration testing in inflammatory bowel disease. Inflamm Bowel Dis. 2015 Jun; 21(6):1435-42. PMID: 25590953.
    Citations: 20     Fields:    Translation:Humans
  105. Feuerstein JD, Cullen G, Cheifetz AS. Immune-mediated reactions to anti-tumor necrosis factors in inflammatory bowel disease. Inflamm Bowel Dis. 2015 May; 21(5):1176-86. PMID: 25581830.
    Citations: 3     Fields:    Translation:Humans
  106. Vaughn BP, Cheifetz AS. It Is Time to Treat to Trough: Staying Ahead of the Curve in Biologic Testing. Clin Gastroenterol Hepatol. 2015 Dec; 13(13):2384. PMID: 25862986.
    Citations: 3     Fields:    Translation:Humans
  107. Gashin L, Villafuerte-Galvez J, Leffler DA, Obuch J, Cheifetz AS. Utility of CT in the emergency department in patients with ulcerative colitis. Inflamm Bowel Dis. 2015 Apr; 21(4):793-800. PMID: 25742397.
    Citations: 3     Fields:    Translation:Humans
  108. Oza SS, Pabby V, Dodge LE, Moragianni VA, Hacker MR, Fox JH, Correia K, Missmer SA, Ibrahim Y, Penzias AS, Burakoff R, Friedman S, Cheifetz AS. In Vitro Fertilization in Women With Inflammatory Bowel Disease Is as Successful as in Women From the General Infertility Population. Clin Gastroenterol Hepatol. 2015 Sep; 13(9):1641-6.e3. PMID: 25818081.
    Citations: 9     Fields:    Translation:Humans
  109. Pabby V, Oza SS, Dodge LE, Hacker MR, Moragianni VA, Correia K, Missmer SA, Fox JH, Ibrahim Y, Penzias A, Burakoff R, Cheifetz A, Friedman S. In Vitro Fertilization Is Successful in Women With Ulcerative Colitis and Ileal Pouch Anal Anastomosis. Am J Gastroenterol. 2015 Jun; 110(6):792-7. PMID: 25512339.
    Citations: 13     Fields:    Translation:Humans
  110. Vaughn BP, Martinez-Vazquez M, Patwardhan VR, Moss AC, Sandborn WJ, Cheifetz AS. Proactive therapeutic concentration monitoring of infliximab may improve outcomes for patients with inflammatory bowel disease: results from a pilot observational study. Inflamm Bowel Dis. 2014 Nov; 20(11):1996-2003. PMID: 25192499.
    Citations: 67     Fields:    Translation:Humans
  111. Feuerstein JD, Lewandowski JJ, Martinez-Vazquez M, Leffler DA, Cheifetz AS. Documented compliance with inflammatory bowel disease quality measures is poor. Dig Dis Sci. 2015 Feb; 60(2):339-44. PMID: 25311583.
    Citations: 10     Fields:    Translation:Humans
  112. Cheifetz A. JAMA patient page. Crohn disease. JAMA. 2014 Oct 22-29; 312(16):1708. PMID: 25335164.
    Citations:    Fields:    Translation:Humans
  113. Feuerstein JD, Cheifetz AS. Ulcerative colitis: epidemiology, diagnosis, and management. Mayo Clin Proc. 2014 Nov; 89(11):1553-63. PMID: 25199861.
    Citations: 66     Fields:    Translation:Humans
  114. Friedman S, Cheifetz AS, Farraye FA, Banks PA, Makrauer FL, Burakoff R, Farmer B, Torgersen LN, Wahl KE. High self-efficacy predicts adherence to surveillance colonoscopy in inflammatory bowel disease. Inflamm Bowel Dis. 2014 Sep; 20(9):1602-10. PMID: 25033161.
    Citations: 3     Fields:    Translation:HumansPHPublic Health
  115. Bai A, Moss A, Kokkotou E, Usheva A, Sun X, Cheifetz A, Zheng Y, Longhi MS, Gao W, Wu Y, Robson SC. CD39 and CD161 modulate Th17 responses in Crohn's disease. J Immunol. 2014 Oct 01; 193(7):3366-77. PMID: 25172498.
    Citations: 45     Fields:    Translation:HumansCellsCTClinical Trials
  116. Feuerstein JD, Leffler DA, Cheifetz AS. Colonoscopy is appropriately utilized in most cases following a fair bowel prep. Am J Gastroenterol. 2014 Aug; 109(8):1289. PMID: 25091247.
    Citations:    Fields:    Translation:Humans
  117. Feuerstein JD, Flier SN, Yee EU, Pleskow D, Cheifetz AS. A rare case series of concomitant inflammatory bowel disease, sporadic adenomas, and serrated polyposis syndrome. J Crohns Colitis. 2014 Dec; 8(12):1735-9. PMID: 25047878.
    Citations: 2     Fields:    Translation:Humans
  118. Feuerstein JD, Cheifetz AS. Miscellaneous adverse events with biologic agents (excludes infection and malignancy). Gastroenterol Clin North Am. 2014 Sep; 43(3):543-63. PMID: 25110258.
    Citations: 10     Fields:    Translation:Humans
  119. Moss AC, Lillis Y, Edwards George JB, Choudhry NK, Berg AH, Cheifetz AS, Horowitz G, Leffler DA. Attitudes to mesalamine questionnaire: a novel tool to predict mesalamine nonadherence in patients with IBD. Am J Gastroenterol. 2014 Dec; 109(12):1850-5. PMID: 24913040.
    Citations: 5     Fields:    Translation:Humans
  120. Feuerstein JD, Leffler DA, Cheifetz AS. In reply--Clinical practice guidelines: still miles to go... Mayo Clin Proc. 2014 Jun; 89(6):860-1. PMID: 24943703.
    Citations:    Fields:    Translation:Humans
  121. Ham M, Longhi MS, Lahiff C, Cheifetz A, Robson S, Moss AC. Vitamin D levels in adults with Crohn's disease are responsive to disease activity and treatment. Inflamm Bowel Dis. 2014 May; 20(5):856-60. PMID: 24681654.
    Citations: 26     Fields:    Translation:HumansCells
  122. Sura SP, Ahmed A, Cheifetz AS, Moss AC. Characteristics of inflammatory bowel disease serology in patients with indeterminate colitis. J Clin Gastroenterol. 2014 Apr; 48(4):351-5. PMID: 24492405.
    Citations: 2     Fields:    Translation:HumansAnimals
  123. Pleet JL, Vaughn BP, Morris JA, Moss AC, Cheifetz AS. The use of pharmacological prophylaxis against venous thromboembolism in hospitalised patients with severe active ulcerative colitis. Aliment Pharmacol Ther. 2014 May; 39(9):940-8. PMID: 24605866.
    Citations: 1     Fields:    Translation:Humans
  124. Devlen J, Beusterien K, Yen L, Ahmed A, Cheifetz AS, Moss AC. Barriers to mesalamine adherence in patients with inflammatory bowel disease: a qualitative analysis. J Manag Care Spec Pharm. 2014 Mar; 20(3):309-14. PMID: 24564811.
    Citations: 7     Fields:    Translation:Humans
  125. Devlen J, Beusterien K, Yen L, Ahmed A, Cheifetz AS, Moss AC. The burden of inflammatory bowel disease: a patient-reported qualitative analysis and development of a conceptual model. Inflamm Bowel Dis. 2014 Mar; 20(3):545-52. PMID: 24407484.
    Citations: 36     Fields:    Translation:Humans
  126. Vaughn BP, Shah S, Cheifetz AS. The role of mucosal healing in the treatment of patients with inflammatory bowel disease. Curr Treat Options Gastroenterol. 2014 Mar; 12(1):103-17. PMID: 24395615.
    Citations: 13     
  127. Longhi MS, Moss A, Bai A, Wu Y, Huang H, Cheifetz A, Quintana FJ, Robson SC. Characterization of human CD39+ Th17 cells with suppressor activity and modulation in inflammatory bowel disease. PLoS One. 2014; 9(2):e87956. PMID: 24505337.
    Citations: 34     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
  128. Feuerstein JD, Akbari M, Gifford AE, Hurley CM, Leffler DA, Sheth SG, Cheifetz AS. Systematic analysis underlying the quality of the scientific evidence and conflicts of interest in interventional medicine subspecialty guidelines. Mayo Clin Proc. 2014 Jan; 89(1):16-24. PMID: 24388018.
    Citations: 12     Fields:    Translation:Humans
  129. Safaie P, Ham M, Kuang P, Mehta AS, Wang M, Cheifetz AS, Robson S, Lau D, Block TM, Moss AC. Lectin-reactive anti-a-gal in patients with Crohn's disease: correlation with clinical phenotypes. Inflamm Bowel Dis. 2013 Dec; 19(13):2796-800. PMID: 24185312.
    Citations: 1     Fields:    Translation:Humans
  130. Feuerstein JD, Leffler DA, Sheth SG, Cheifetz AS. An appraisal of the current state of gastroenterology practice guidelines. Gastroenterology. 2013 Dec; 145(6):1175-8. PMID: 24409477.
    Citations:    Fields:    Translation:Humans
  131. Lahiff C, Cheifetz AS. The holistic effects of cannabis in Crohn's disease. Clin Gastroenterol Hepatol. 2014 May; 12(5):898. PMID: 24262941.
    Citations: 1     Fields:    Translation:Humans
  132. Feuerstein JD, Gifford AE, Akbari M, Goldman J, Leffler DA, Sheth SG, Cheifetz AS. Systematic analysis underlying the quality of the scientific evidence and conflicts of interest in gastroenterology practice guidelines. Am J Gastroenterol. 2013 Nov; 108(11):1686-93. PMID: 24192942.
    Citations: 9     Fields:    Translation:Humans
  133. Juillerat P, Wasan SK, Fowler SA, Friedman S, Pabby VK, Coukas JA, Barto AE, Pellish R, Germansky KA, Cheifetz AS, Korzenik JR, Farraye FA, Yajnik V. Efficacy and safety of natalizumab in Crohn's disease patients treated at 6 Boston academic hospitals. Inflamm Bowel Dis. 2013 Oct; 19(11):2457-63. PMID: 23962896.
    Citations: 11     Fields:    Translation:Humans
  134. Feuerstein JD, Feuerstien JD, Najarian R, Cheifetz AS. Hickam's dictum in a patient with diarrhea. Gastroenterology. 2013 Nov; 145(5):942, 1165. PMID: 24070726.
    Citations:    Fields:    Translation:Humans
  135. Feuerstein JD, Leffler DA, Cheifetz AS. Letter: inflammatory bowel disease guidelines and conflicts of interest--authors' reply. Aliment Pharmacol Ther. 2013 Aug; 38(4):445-6. PMID: 23855400.
    Citations:    Fields:    Translation:Humans
  136. Feuerstein JD, Leffler DA, Cheifetz AS. Letter: international IBD practice guidelines -- authors' reply. Aliment Pharmacol Ther. 2013 Aug; 38(3):326-7. PMID: 23808419.
    Citations:    Fields:    Translation:Humans
  137. Cheifetz AS. Management of active Crohn disease. JAMA. 2013 May 22; 309(20):2150-8. PMID: 23695484.
    Citations: 37     Fields:    Translation:Humans
  138. Ferreira J, Akbari M, Gashin L, Cullen G, Moss A, Leffler DA, Aronson M, Cheifetz AS. Prevalence and lifetime risk of endoscopy-related complications among patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2013 Oct; 11(10):1288-93. PMID: 23669305.
    Citations: 3     Fields:    Translation:Humans
  139. Lahiff C, Cheifetz AS. Commentary: irritable bowel syndrome and the CDAI--misleading activity by straw men; authors' reply. Aliment Pharmacol Ther. 2013 May; 37(10):1021-2. PMID: 23590539.
    Citations:    Fields:    Translation:Humans
  140. Rosenberg L, Nanda KS, Zenlea T, Gifford A, Lawlor GO, Falchuk KR, Wolf JL, Cheifetz AS, Goldsmith JD, Moss AC. Histologic markers of inflammation in patients with ulcerative colitis in clinical remission. Clin Gastroenterol Hepatol. 2013 Aug; 11(8):991-6. PMID: 23591275.
    Citations: 36     Fields:    Translation:Humans
  141. Feuerstein JD, Akbari M, Gifford AE, Cullen G, Leffler DA, Sheth SG, Cheifetz AS. Systematic review: the quality of the scientific evidence and conflicts of interest in international inflammatory bowel disease practice guidelines. Aliment Pharmacol Ther. 2013 May; 37(10):937-46. PMID: 23550536.
    Citations: 12     Fields:    Translation:Humans
  142. Cullen G, Donnellan F, Doherty GA, Smith M, Cheifetz AS. Evaluation of the small bowel in inflammatory bowel disease. Expert Rev Gastroenterol Hepatol. 2013 Mar; 7(3):239-51. PMID: 23445233.
    Citations: 3     Fields:    Translation:Humans
  143. Rosenberg L, Lawlor GO, Zenlea T, Goldsmith JD, Gifford A, Falchuk KR, Wolf JL, Cheifetz AS, Robson SC, Moss AC. Predictors of endoscopic inflammation in patients with ulcerative colitis in clinical remission. Inflamm Bowel Dis. 2013 Mar-Apr; 19(4):779-84. PMID: 23446338.
    Citations: 36     Fields:    Translation:HumansCellsCTClinical Trials
  144. Friedman S, Cheifetz AS, Farraye FA, Banks PA, Makrauer FL, Burakoff R, Farmer B, Torgersen LN, Wahl KE. Factors that affect adherence to surveillance colonoscopy in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2013 Mar; 19(3):534-9. PMID: 23429444.
    Citations: 11     Fields:    Translation:Humans
  145. Lahiff C, Safaie P, Awais A, Akbari M, Gashin L, Sheth S, Lembo A, Leffler D, Moss AC, Cheifetz AS. The Crohn's disease activity index (CDAI) is similarly elevated in patients with Crohn's disease and in patients with irritable bowel syndrome. Aliment Pharmacol Ther. 2013 Apr; 37(8):786-94. PMID: 23432394.
    Citations: 29     Fields:    Translation:Humans
  146. Gifford AE, Berg AH, Lahiff C, Cheifetz AS, Horowitz G, Moss AC. A random urine test can identify patients at risk of mesalamine non-adherence: a prospective study. Am J Gastroenterol. 2013 Feb; 108(2):249-55. PMID: 23295279.
    Citations: 7     Fields:    Translation:HumansPHPublic Health
  147. Akbari M, Shah S, Velayos FS, Mahadevan U, Cheifetz AS. Systematic review and meta-analysis on the effects of thiopurines on birth outcomes from female and male patients with inflammatory bowel disease. Inflamm Bowel Dis. 2013 Jan; 19(1):15-22. PMID: 22434610.
    Citations: 49     Fields:    Translation:Humans
  148. Ham M, Cullen G, Cheifetz AS. Varicella zoster virus infection in patients with inflammatory bowel disease. Gastroenterol Hepatol (N Y). 2013 Jan; 9(1):56-8. PMID: 24707238.
    Citations: 4     
  149. Feuerstein JD, Leffler DA, Cheifetz AS. How physicians interpret research funding disclosures. N Engl J Med. 2012 12 13; 367(24):2358-9; author reply 2360. PMID: 23234527.
    Citations:    Fields:    Translation:Humans
  150. Nanda KS, Cheifetz AS, Moss AC. Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis. Am J Gastroenterol. 2013 Jan; 108(1):40-7; quiz 48. PMID: 23147525.
    Citations: 106     Fields:    Translation:Humans
  151. Doherty GA, Bai A, Hanidziar D, Longhi MS, Lawlor GO, Putheti P, Csizmadia E, Nowak M, Cheifetz AS, Moss AC, Robson SC. CD73 is a phenotypic marker of effector memory Th17 cells in inflammatory bowel disease. Eur J Immunol. 2012 Nov; 42(11):3062-72. PMID: 22965858.
    Citations: 35     Fields:    Translation:HumansCells
  152. Feuerstein JD, Cheifetz AS, Siegel CA. Comparative effectiveness research in inflammatory bowel disease: prospects and challenges. Expert Rev Gastroenterol Hepatol. 2012 Aug; 6(4):405-7. PMID: 22928891.
    Citations:    Fields:    Translation:Humans
  153. Cullen G, Cheifetz AS. Infusion reactions related to infliximab therapy are not usually associated with drug discontinuation. J Rheumatol. 2012 Aug; 39(8):1500-2. PMID: 22859528.
    Citations: 1     Fields:    Translation:Humans
  154. Ferreira J, Grochowsky J, Krakower D, Zuromskis P, Baden R, Cheifetz AS. Mycobacterium marinum: an increasingly common opportunistic infection in patients on infliximab. Am J Gastroenterol. 2012 Aug; 107(8):1268-9. PMID: 22859009.
    Citations: 3     Fields:    Translation:HumansCells
  155. Cullen G, Baden RP, Cheifetz AS. Varicella zoster virus infection in inflammatory bowel disease. Inflamm Bowel Dis. 2012 Dec; 18(12):2392-403. PMID: 22434654.
    Citations: 26     Fields:    Translation:HumansCells
  156. Cheifetz AS, Melmed GY, Spiegel B, Talley J, Devlin SM, Raffals L, Irving PM, Jones J, Kaplan GG, Kozuch P, Sparrow M, Velayos F, Baidoo L, Bressler B, Siegel CA. Setting priorities for comparative effectiveness research in inflammatory bowel disease: results of an international provider survey, expert RAND panel, and patient focus groups. Inflamm Bowel Dis. 2012 Dec; 18(12):2294-300. PMID: 22337359.
    Citations: 3     Fields:    Translation:Humans
  157. Devlin SM, Cheifetz AS, Siegel CA. Patient-specific approach to combination versus monotherapy with the use of antitumor necrosis factor a agents for inflammatory bowel disease. Gastroenterol Clin North Am. 2012 Jun; 41(2):411-28. PMID: 22500526.
    Citations: 4     Fields:    Translation:Humans
  158. Rostholder E, Ahmed A, Cheifetz AS, Moss AC. Outcomes after escalation of infliximab therapy in ambulatory patients with moderately active ulcerative colitis. Aliment Pharmacol Ther. 2012 Mar; 35(5):562-7. PMID: 22239070.
    Citations: 14     Fields:    Translation:Humans
  159. Cullen G, Kroshinsky D, Cheifetz AS, Korzenik JR. Psoriasis associated with anti-tumour necrosis factor therapy in inflammatory bowel disease: a new series and a review of 120 cases from the literature. Aliment Pharmacol Ther. 2011 Dec; 34(11-12):1318-27. PMID: 21957906.
    Citations: 37     Fields:    Translation:Humans
  160. Vaughn BP, Doherty GA, Gautam S, Moss AC, Cheifetz AS. Screening for tuberculosis and hepatitis B prior to the initiation of anti-tumor necrosis therapy. Inflamm Bowel Dis. 2012 Jun; 18(6):1057-63. PMID: 21953829.
    Citations: 22     Fields:    Translation:HumansCells
  161. Friedman S, Cheifetz AS, Farraye FA, Banks PA, Makrauer FL, Burakoff R, Farmer B, Torgersen LN, Wahl KE. Doctor message can alter patients' behavior and attitudes regarding inflammatory bowel disease and colon cancer. Inflamm Bowel Dis. 2012 Aug; 18(8):1531-9. PMID: 21928374.
    Citations: 2     Fields:    Translation:Humans
  162. Doherty GA, Miksad RA, Cheifetz AS, Moss AC. Comparative cost-effectiveness of strategies to prevent postoperative clinical recurrence of Crohn's disease. Inflamm Bowel Dis. 2012 Sep; 18(9):1608-16. PMID: 21905173.
    Citations: 13     Fields:    Translation:HumansPHPublic Health
  163. Ferreira J, Baden R, Magge S, Cheifetz A. Cryptosporidiosis masquerading as a Crohn's flare. Inflamm Bowel Dis. 2011 Oct; 17(10):E133-4. PMID: 21739536.
    Citations: 2     Fields:    Translation:HumansAnimals
  164. Cullen G, Vaughn B, Ahmed A, Peppercorn MA, Smith MP, Moss AC, Cheifetz AS. Abdominal phlegmons in Crohn's disease: outcomes following antitumor necrosis factor therapy. Inflamm Bowel Dis. 2012 Apr; 18(4):691-6. PMID: 21648022.
    Citations: 9     Fields:    Translation:Humans
  165. Cullen G, Krakower D, Mitty JA, Cheifetz AS. Varicella zoster meningoradiculitis in Crohn's disease treated with 6-mercaptopurine. Inflamm Bowel Dis. 2011 Aug; 17(8):E109-10. PMID: 21618366.
    Citations: 1     Fields:    Translation:HumansCells
  166. Doherty GA, Moss AC, Cheifetz AS. Capsule endoscopy for small-bowel evaluation in Crohn's disease. Gastrointest Endosc. 2011 Jul; 74(1):167-75. PMID: 21497806.
    Citations: 15     Fields:    Translation:Humans
  167. Cheifetz AS, Stern J, Garud S, Goldstein E, Malter L, Moss AC, Present DH. Cyclosporine is safe and effective in patients with severe ulcerative colitis. J Clin Gastroenterol. 2011 Feb; 45(2):107-12. PMID: 20679905.
    Citations: 15     Fields:    Translation:Humans
  168. Cullen G, Baden RP, Cheifetz AS. Vaccination in inflammatory bowel disease. Am J Gastroenterol. 2011 Jan; 106(1):168. PMID: 21212760.
    Citations:    Fields:    Translation:HumansPHPublic Health
  169. Cheifetz AS, Rosenberg L. Infliximab decreases colectomy rates in moderate to severe ulcerative colitis: big news or big deal? Inflamm Bowel Dis. 2011 Jul; 17(7):1626-8. PMID: 21053245.
    Citations: 1     Fields:    
  170. Doherty GA, Moss AC, Cheifetz AS. Capsule endoscopy in suspected Crohn's disease: "yield" does not equal "diagnosis". Am J Gastroenterol. 2010 Sep; 105(9):2111; author reply 2111-2. PMID: 20818355.
    Citations: 6     Fields:    Translation:Humans
  171. Melmed GY, Spiegel BM, Bressler B, Cheifetz AS, Devlin SM, Harrell LE, Irving PM, Jones J, Kaplan GG, Kozuch PL, Velayos FS, Baidoo L, Sparrow MP, Siegel CA. The appropriateness of concomitant immunomodulators with anti-tumor necrosis factor agents for Crohn's disease: one size does not fit all. Clin Gastroenterol Hepatol. 2010 Aug; 8(8):655-9. PMID: 20451665.
    Citations: 11     Fields:    Translation:Humans
  172. Doherty GA, Bennett GC, Cheifetz AS, Moss AC. Meta-analysis: targeting the intestinal microbiota in prophylaxis for post-operative Crohn's disease. Aliment Pharmacol Ther. 2010 Apr; 31(8):802-9. PMID: 20055785.
    Citations: 20     Fields:    Translation:HumansPHPublic Health
  173. Moss AC, Chaudhary N, Tukey M, Junior J, Cury D, Falchuk KR, Cheifetz AS. Impact of a patient-support program on mesalamine adherence in patients with ulcerative colitis--a prospective study. J Crohns Colitis. 2010 Jun; 4(2):171-5. PMID: 21122501.
    Citations: 10     Fields:    Translation:Humans
  174. Doherty G, Bennett G, Patil S, Cheifetz A, Moss AC. Interventions for prevention of post-operative recurrence of Crohn's disease. Cochrane Database Syst Rev. 2009 Oct 07; (4):CD006873. PMID: 19821389.
    Citations: 66     Fields:    Translation:HumansPHPublic Health
  175. Doherty GA, Cheifetz AS. Management of acute severe ulcerative colitis. Expert Rev Gastroenterol Hepatol. 2009 Aug; 3(4):395-405. PMID: 19673626.
    Citations: 6     Fields:    Translation:Humans
  176. Tukey M, Pleskow D, Legnani P, Cheifetz AS, Moss AC. The utility of capsule endoscopy in patients with suspected Crohn's disease. Am J Gastroenterol. 2009 Nov; 104(11):2734-9. PMID: 19584828.
    Citations: 33     Fields:    Translation:Humans
  177. Moss AC, Kim KJ, Fernandez-Becker N, Cury D, Cheifetz AS. Impact of concomitant immunomodulator use on long-term outcomes in patients receiving scheduled maintenance infliximab. Dig Dis Sci. 2010 May; 55(5):1413-20. PMID: 19533357.
    Citations: 5     Fields:    Translation:Humans
  178. Doherty GA, Cheifetz AS. Targeting TNF in postoperative recurrence of Crohn's disease: can we extinguish the fire before it starts? Inflamm Bowel Dis. 2009 Dec; 15(12):1925-6. PMID: 19462427.
    Citations: 1     Fields:    
  179. Moss AC, Cheifetz AS. How often is a diagnosis of ulcerative colitis changed to Crohn's disease and vice versa? Inflamm Bowel Dis. 2008 Oct; 14 Suppl 2:S155-6. PMID: 18816774.
    Citations: 4     Fields:    Translation:Humans
  180. Sparrow MP, Irving PM, Baidoo L, Bressler B, Cheifetz AS, Devlin SM, Harrell LE, Jones J, Kozuch PL, Melmed GY, Velayos FS, Siegel CA. Current Controversies in Crohn's Disease: A Roundtable Discussion of the BRIDGe Group. Gastroenterol Hepatol (N Y). 2008 Oct; 4(10):713-20. PMID: 21960891.
    Citations:    
  181. Kokkotou E, Moss AC, Torres D, Karagiannides I, Cheifetz A, Liu S, O'Brien M, Maratos-Flier E, Pothoulakis C. Melanin-concentrating hormone as a mediator of intestinal inflammation. Proc Natl Acad Sci U S A. 2008 Jul 29; 105(30):10613-8. PMID: 18650383.
    Citations: 29     Fields:    Translation:HumansAnimals
  182. Moss AC, Fernandez-Becker N, Jo Kim K, Cury D, Cheifetz AS. The impact of infliximab infusion reactions on long-term outcomes in patients with Crohn's disease. Aliment Pharmacol Ther. 2008 Jul; 28(2):221-7. PMID: 18485127.
    Citations: 9     Fields:    Translation:Humans
  183. Leffler D, Cheifetz A, Chiefetz A. Forecasting the recurrence of ulcerative colitis: can U.C. the future? Inflamm Bowel Dis. 2008 Mar; 14(3):422-4. PMID: 17973306.
    Citations: 1     Fields:    Translation:Humans
  184. Garud S, Brown A, Cheifetz A, Levitan EB, Kelly CP. Meta-analysis of the placebo response in ulcerative colitis. Dig Dis Sci. 2008 Apr; 53(4):875-91. PMID: 17934839.
    Citations: 5     Fields:    Translation:Humans
  185. Moss AC, Cheifetz AS. Reducing the torment of diarrhea: tormentil for active ulcerative colitis. J Clin Gastroenterol. 2007 Oct; 41(9):797-8. PMID: 17881923.
    Citations: 1     Fields:    Translation:HumansAnimals
  186. Moss AC, Anton P, Savidge T, Newman P, Cheifetz AS, Gay J, Paraschos S, Winter MW, Moyer MP, Karalis K, Kokkotou E, Pothoulakis C. Urocortin II mediates pro-inflammatory effects in human colonocytes via corticotropin-releasing hormone receptor 2alpha. Gut. 2007 Sep; 56(9):1210-7. PMID: 17412781.
    Citations: 36     Fields:    Translation:HumansAnimalsCells
  187. Moss AC, Treister NS, Marsee DK, Cheifetz AS. Clinical challenges and images in GI. Oral lichenoid reaction in a patient with Crohn's disease receiving infliximab. Gastroenterology. 2007 Feb; 132(2):488, 829. PMID: 17261307.
    Citations: 3     Fields:    Translation:Humans
  188. Cheifetz AS, Lewis BS. Capsule endoscopy retention: is it a complication? J Clin Gastroenterol. 2006 Sep; 40(8):688-91. PMID: 16940879.
    Citations: 37     Fields:    Translation:Humans
  189. Cheifetz AS, Kornbluth AA, Legnani P, Schmelkin I, Brown A, Lichtiger S, Lewis BS. The risk of retention of the capsule endoscope in patients with known or suspected Crohn's disease. Am J Gastroenterol. 2006 Oct; 101(10):2218-22. PMID: 16848804.
    Citations: 93     Fields:    Translation:Humans
  190. Moss AC, Cheifetz AS, Peppercorn MA. Combined oral and topical mesalazine treatment for extensive ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol. 2006 May; 3(5):290-3. PMID: 16673009.
    Citations: 2     Fields:    Translation:Humans
  191. Kraus TA, Cheifetz A, Toy L, Meddings JB, Mayer L. Evidence for a genetic defect in oral tolerance induction in inflammatory bowel disease. Inflamm Bowel Dis. 2006 Feb; 12(2):82-8; discussion 81. PMID: 16432371.
    Citations: 13     Fields:    Translation:Humans
  192. Moss AC, Brennan AM, Cheifetz AS, Peppercorn MA. Thyroid cancer and Crohn's disease: association or coincidence? Inflamm Bowel Dis. 2006 Jan; 12(1):79-80. PMID: 16374265.
    Citations: 3     Fields:    Translation:Humans
  193. Thukral C, Cheifetz A, Peppercorn MA. Anti-tumour necrosis factor therapy for ulcerative colitis: evidence to date. Drugs. 2006; 66(16):2059-65. PMID: 17112300.
    Citations: 7     Fields:    Translation:Humans
  194. Cheifetz A, Mayer L. Monoclonal antibodies, immunogenicity, and associated infusion reactions. Mt Sinai J Med. 2005 Jul; 72(4):250-6. PMID: 16021319.
    Citations: 32     Fields:    Translation:Humans
  195. Travassos WJ, Cheifetz AS. Infliximab: Use in Inflammatory Bowel Disease. Curr Treat Options Gastroenterol. 2005 Jun; 8(3):187-196. PMID: 15913508.
    Citations: 11     
  196. Cheifetz A, Mayer L. Monoclonal Antibodies, Immunogenicity, and Associated Infusion Reactions. Mount Sinai Journal (in press). 2005.
  197. Travassos W, Cheifetz A. Infliximab: Use in Inflammatory Bowel Disease. Current Treatment Options in Castroenterology (in press). 2005.
  198. Kraus T, Cheifetz A, Toy L, Mayer L. Monoclonal Antibodies, Immunogenicity, and Associated Infusion Reactions. Inflammatory Bowel Diseases (submitted). 2005.
  199. Kraus TA, Toy L, Chan L, Childs J, Cheifetz A, Mayer L. Failure to induce oral tolerance in Crohn's and ulcerative colitis patients: possible genetic risk. Ann N Y Acad Sci. 2004 Dec; 1029:225-38. PMID: 15681761.
    Citations: 11     Fields:    Translation:HumansCTClinical Trials
  200. Cheifetz AS. You say goodbye and I say aloe. Inflamm Bowel Dis. 2004 Sep; 10(5):693-5. PMID: 15472535.
    Citations:    Fields:    
  201. Cheifetz A, Itzkowitz S. The diagnosis and treatment of pouchitis in inflammatory bowel disease. J Clin Gastroenterol. 2004 May-Jun; 38(5 Suppl 1):S44-50. PMID: 15115932.
    Citations: 6     Fields:    Translation:Humans
  202. Cheifetz A, Kornbluth A, Legnani P, Lichtiger S, Lewis B. Crohn's Disease and the Retained Capsule Endoscope (CE): A "Therapeutic Complication" [Abstract]. American Journal of Gastroenterology. 2004; suppl..
  203. Cheifetz A, Sachar D, Lewis B. Small Bowel Obstruction – Indication or Contraindication for Capsule Endoscopy? [Abstract]. Gastrointestinal Endoscopy. 2004; suppl.
  204. Cheifetz A, Smedley M, Martin S, Reiter M, Leone G, Mayer L, Plevy S. The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol. 2003 Jun; 98(6):1315-24. PMID: 12818276.
    Citations: 96     Fields:    Translation:Humans
  205. Cheifetz A, Smedley M, Martin S, Reiter M, Leone G, Mayer L, Plevy S. The Incidence and Management of Acute Infusion Reactions to Infliximab: A Large Center Experience. American Journal of Gastroenterology. 2003; 98:1315-1324.
  206. Cheifetz A. Management of the child with neurofibromatosis Type I, von Recklinghausen Disease. Penn Dent J (Phila). 2001; 101:5, 8, 32. PMID: 15484633.
    Citations:    Fields:    Translation:Humans
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact contactcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Cheifetz's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (464)